Effect of CYP3A5 and MDR1 gene polymorphism on  blood concentration of tacrolimus and creatinine level in uremic patients during the early phase of kidney transplantation

WEN Yan; ZHU Dekang; FU Shangxi; DENGYi; ZHANG Feng; CHEN Wansheng

doi:10.12206/j.issn.1006-0111.202009087

Volume 40 Issue 2

Mar. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2022 > 40(2): 165-170

WEN Yan, ZHU Dekang, FU Shangxi, DENGYi, ZHANG Feng, CHEN Wansheng. Effect of CYP3A5 and MDR1 gene polymorphism on blood concentration of tacrolimus and creatinine level in uremic patients during the early phase of kidney transplantation[J]. Journal of Pharmaceutical Practice and Service, 2022, 40(2): 165-170. doi: 10.12206/j.issn.1006-0111.202009087

Citation:

WEN Yan, ZHU Dekang, FU Shangxi, DENGYi, ZHANG Feng, CHEN Wansheng. Effect of CYP3A5 and MDR1 gene polymorphism on blood concentration of tacrolimus and creatinine level in uremic patients during the early phase of kidney transplantation[J]. Journal of Pharmaceutical Practice and Service, 2022, 40(2): 165-170. doi: 10.12206/j.issn.1006-0111.202009087

Effect of CYP3A5 and MDR1 gene polymorphism on blood concentration of tacrolimus and creatinine level in uremic patients during the early phase of kidney transplantation

doi: 10.12206/j.issn.1006-0111.202009087

1.
Naval Medical University of the PLA: a. Department of Pharmacy, Second affiliated Hospital, Shanghai 200003, b. Department of Academic Administrative Affairs, Shanghai 200433, China, c. Department of Organ Transplantation, Shanghai 200003, China
2.
Naval Medical University of the PLA: a. Department of Pharmacy, Second affiliated Hospital, Shanghai 200003, b. Department of Academic Administrative Affairs, Shanghai 200433, China, c. Department of Organ Transplantation, Shanghai 200003, China
3.
Naval Medical University of the PLA: a. Department of Pharmacy, Second affiliated Hospital, Shanghai 200003, b. Department of Academic Administrative Affairs, Shanghai 200433, China, c. Department of Organ Transplantation, Shanghai 200003, China

Received Date: 2020-09-26
Rev Recd Date: 2022-01-04

Available Online: 2022-03-29

Publish Date: 2022-03-25

Abstract

Objective To investigate the effect of CYP3A5 and MDR1 gene polymorphisms on blood concentration of tacrolimus and creatinine level in uremic patients during the early phase after kidney transplantation in real clinical practice. Methods 131 patients who underwent kidney transplantation for the first time with triple immunotherapy based on tacrolimus in single-center from 2013 to 2017 were enrolled for retrospective study. Tacrolimus daily dose, blood concentration, blood concentration-to-dose ratio, and serum level were compared according to the various genotypes of CYP3A5 and MDR1 polymorphisms in renal transplantation recipients, respectively. Results The dosage of tacrolimus in CYP3A5*3/*3 (GG) kidney transplantation recipients within 4 weeks after kidney transplantation was lower than those of CYP3A5*1/*1 (AA) and CYP3A5*1/*3 (AG). The serum creatinine levels of patients whose tacrolimus concentration in the range of 10-13 ng/ml were close to the normal value. Conclusion CYP3A5 gene polymorphism affects the blood concentrations of tacrolimus in renal transplant recipients. No association has been found between the blood concentrations of tacrolimus and MDR1 gene polymorphism. Tacrolimus concentration in the range of 10-13 ng/ml might contribute to restore the early kidney graft function.
- tacrolimus,
- kidney transplantation,
- creatinine,
- CYP3A5,
- MDR1

References

[1]	石炳毅, 袁铭. 中国肾移植受者免疫抑制治疗指南(2016 版)[J]. 器官移植, 2016, 7(5):327-331. doi: 10.3969/j.issn.1674-7445.2016.05.001
[2]	RODRÍGUEZ FABA O, BOISSIER R, BUDDE K, et al. European association of urology guidelines on renal transplantation: update 2018[J]. Eur Urol Focus,2018,4(2):208-215. doi: 10.1016/j.euf.2018.07.014
[3]	BENTATA Y. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxi-city[J]. Artif Organs,2020,44(2):140-152. doi: 10.1111/aor.13551
[4]	SHRESTHA B M. Two decades of tacrolimus in renal transplant: basic science and clinical evidences[J]. Exp Clin Transplant,2017,15(1):1-9.
[5]	VAN GELDER T, VAN SCHAIK R H, HESSELINK D A. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation[J]. Nat Rev Nephrol,2014,10(12):725-731. doi: 10.1038/nrneph.2014.172
[6]	EVANS W E, MCLEOD H L. Pharmacogenomics: drug disposition, drug targets, and side effects[J]. N Engl J Med,2003,348(6):538-549. doi: 10.1056/NEJMra020526
[7]	田普训, 敖建华, 李宁, 等. 器官移植免疫抑制剂临床应用技术规范(2019版)[J]. 器官移植, 2019, 10(3):213-226. doi: 10.3969/j.issn.1674-7445.2019.03.001
[8]	LIABEUF S, CHEDDANI L, MASSY Z. Uremic toxins and clinical outcomes: the impact of kidney transplantation[J]. Toxins (Basel). 2018, 10 (6): 229.
[9]	ANGLICHEAU D, VERSTUYFT C, LAURENT-PUIG P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients[J]. J Am Soc Nephrol,2003,14(7):1889-1896. doi: 10.1097/01.ASN.0000073901.94759.36
[10]	HU Y F, HE J, CHEN G L, et al. CYP3A53 and CYP3A418 single nucleotide polymorphisms in a Chinese population[J]. Clin Chim Acta,2005,353(1-2):187-192. doi: 10.1016/j.cccn.2004.11.005
[11]	赵富磊, 李骞, 张峻. 基因多态性对肾移植患者他克莫司药代动力学影响的研究现状[J]. 中国临床药理学杂志, 2017, 33(23):2489-2492.
[12]	PRASAD N, JAISWAL A, BEHERA M R, et al. Melding pharmacogenomic effect of MDR1 and CYP3A5 gene polymorphism on tacrolimus dosing in renal transplant recipients in northern India[J]. Kidney Int Rep,2020,5(1):28-38. doi: 10.1016/j.ekir.2019.09.013
[13]	FREDERICKS S, MORETON M, REBOUX S, et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements[J]. Transplantation,2006,82(5):705-708. doi: 10.1097/01.tp.0000234942.78716.c0
[14]	LOH P T, LOU H X, ZHAO Y, et al. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients[J]. Transplant Proc,2008,40(5):1690-1695. doi: 10.1016/j.transproceed.2008.04.010
[15]	GERVASINI G, GARCIA M, MACIAS R M, et al. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation[J]. Transpl Int,2012,25(4):471-480. doi: 10.1111/j.1432-2277.2012.01446.x

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(3) / Tables(6)

Get Citation

PDF

XML

Article Metrics

Article views(4284) PDF downloads(25) Cited by()

Proportional views

HTML

钙调神经磷酸酶抑制剂（CNI）于20世纪90年代引入器官移植领域，是大多数实体器官移植免疫抑制方案的基石^[1-2]。目前，94%的肾移植受者在移植后使用基于CNI的免疫抑制方案出院，90%以上的受者接受他克莫司治疗^[3-4]。他克莫司主要通过细胞色素P450（如CYP3A4和CYP3A5等）代谢，由P-糖蛋白（P-gp）进行转运。研究表明，CYP3A5酶是他克莫司在人体主要的代谢酶，MDR1（编码P-gp的基因）的基因多态性也是肾移植术后他克莫司血药浓度的影响因素^[5-6]。

《器官移植免疫抑制剂临床应用技术》（2019版）建议他克莫司服药后一个月内血药浓度需控制在8～12 ng/ml^[7]，各移植中心的靶浓度根据具体给药方案、血药浓度检测试剂盒的规定而确定。我院器官移植中心靶浓度为10～15 ng/ml。但由于通常器官移植术后 5～7 d他克莫司的药物浓度达到稳态，这使得他克莫司首次给药剂量与首次的血药浓度检测值可能存在一定的时间差，因此需要尽早对给药剂量进行干预，以达到提高他克莫司的疗效和减少其不良反应的目的。

由于肾功能通常不会在肾移植术后完全恢复，移植受者具有慢性肾脏病第2或第3期的特征^[8]，因此，本研究对我院在2013年至2017年做肾移植手术的尿毒症患者的CYP3A5（CYP3A5*3，6986A>G）及MDR1（C3435>T，G2677 >T/A，C1236>T）基因型进行检测，探讨其对于他克莫司血药浓度、血药浓度/剂量比值的影响，以及与最佳治疗浓度范围和患者肌酐水平的相关性，为开展早期肾移植患者的免疫抑制剂个体化管理，避免浓度过低造成免疫不足或浓度过高产生不良反应提供依据。

3. 讨论

在《中国肾移植后免疫抑制治疗指南》中，他克莫司+霉酚酸类药物+激素类药物的三联疗法已经成为临床上治疗肾移植后免疫排斥反应的默认疗法。指南中规定，以肾移植受者服用他克莫司后次日晨服药前的谷浓度作为检测指标，在接受手术后1个月内血药浓度要控制在10～15 ng/ml，3个月以内为8～15 ng/ml，一年以内为5-12 ng/ml^[1]。本研究发现肾移植术后1个月时，为了维持目标血药浓度，不同受者之间他克莫司所需要的剂量差异最高可高达16.6倍，此情况与前期文献报道的最大差异可高达12倍的情况一致^[9]。

研究发现，CYP3A5*3的基因型突变出现在中国人群中的概率高达78.8%^[10]，因此， CYP3A5基因型检测已经成为目前器官移植患者使用他克莫司个体化给药的必备手段。本研究的结果表明，术后1～4周基因型为AG的患者在给药剂量及浓度剂量比方面与基因型为GG的患者存在显著性差异（P<0.05），术后2～4周基因型为AA的患者在给药剂量及浓度剂量比方面与基因型为GG的患者存在显著性差异（P<0.05）。CYP3A5*3等位基因的存在对他克莫司血药浓度具有显著性影响。可以看出不同基因型的患者在他克莫司血药浓度维持在治疗浓度的时候，带有CYP3A5*3等位基因的患者给药剂量小于带有CYP3A5*1等位基因的患者。浓度/剂量比也反映了CYP3A5等位基因的出现会导致他克莫司代谢的降低，而且CYP3A5*3等位基因的数量越多，对代谢的影响就越大。即对他克莫司的代谢速率，纯合子>杂合子>野生型，野生型的基因型代谢速率可能近似于杂合子和纯合子的50%～70%。因此，在临床上对这类患者需要降低他克莫司的给药剂量，以避免出现毒副作用。

对于不同MDR1基因型的患者，仅发现患者为MDR1（G2677T/A）基因的情况下，术后第2周他克莫司血药浓度具有显著性差异（P<0.05），其余均无显著性差异。在131例肾移植受者中，仅有1例MDR1（G2677T/A）AA的患者，可能导致分析的不准确。现有关于MDR1基因多态性对他克莫司血药浓度的影响意见也各不相同。Meta分析显示亚洲人群肾移植患者术后他克莫司血药浓度/剂量值与MDR1基因C3435T多态性相关, 其相关性为TT>CT>CC。有报道认为MDR1基因G2677T/A突变型的患者中, 他克莫司的血药浓度比野生型个体高44.7%^[11]。本研究表明，CYP3A5（*1*1）每日对他克莫司剂量需求最高，CYP3A5（*3*3）最低，与文献报道一致^[12]。以往的研究表明，当CYP3A5基因型出现突变时，MDR1基因对他克莫司血药浓度的影响很小^[13-14]。如果将研究局限于CYP3A5基因型为AA的患者中，则携带4～6个MDR1等位基因的患者较携带0～3个等位基因的患者具有较高的剂量要求^[15]。由于本研究中CYP3A5基因型为AA的患者仅有7例，受限于样本量过小，难以说明MDR1基因型对于他克莫司血药浓度的影响。

临床实践和众多的文献表明，遗传因素是造成肾移植受者他克莫司谷浓度及浓度/剂量比个体差异的重要原因，我们的研究结果也与之一致。更重要的是，我们发现同一基因型的患者，他克莫司的浓度/剂量比在早期呈现逐渐减小的趋势，与之对应的给药剂量随着移植时间延长逐渐减小，且肌酐逐渐降低接近至正常人水平，说明患者肾功能处于恢复期。当患者血药浓度为10～13 ng/ml的时候，患者移植的肾功能最接近正常人肾功能水平。因此，采用现代分子生物学技术在移植术前检测患者的基因型，这对依据其基因型确定器官移植术后免疫抑制剂的剂量、改善患者预后有重要的指导意义。

Reference (15)

[1]	石炳毅, 袁铭. 中国肾移植受者免疫抑制治疗指南(2016 版)[J]. 器官移植, 2016, 7(5):327-331.
[2]	RODRÍGUEZ FABA O, BOISSIER R, BUDDE K, et al. European association of urology guidelines on renal transplantation: update 2018[J]. Eur Urol Focus,2018,4(2):208-215.
[3]	BENTATA Y. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxi-city[J]. Artif Organs,2020,44(2):140-152.
[4]	SHRESTHA B M. Two decades of tacrolimus in renal transplant: basic science and clinical evidences[J]. Exp Clin Transplant,2017,15(1):1-9.
[5]	VAN GELDER T, VAN SCHAIK R H, HESSELINK D A. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation[J]. Nat Rev Nephrol,2014,10(12):725-731.
[6]	EVANS W E, MCLEOD H L. Pharmacogenomics: drug disposition, drug targets, and side effects[J]. N Engl J Med,2003,348(6):538-549.
[7]	田普训, 敖建华, 李宁, 等. 器官移植免疫抑制剂临床应用技术规范(2019版)[J]. 器官移植, 2019, 10(3):213-226.
[8]	LIABEUF S, CHEDDANI L, MASSY Z. Uremic toxins and clinical outcomes: the impact of kidney transplantation[J]. Toxins (Basel). 2018, 10 (6): 229.
[9]	ANGLICHEAU D, VERSTUYFT C, LAURENT-PUIG P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients[J]. J Am Soc Nephrol,2003,14(7):1889-1896.
[10]	HU Y F, HE J, CHEN G L, et al. CYP3A53 and CYP3A418 single nucleotide polymorphisms in a Chinese population[J]. Clin Chim Acta,2005,353(1-2):187-192.
[11]	赵富磊, 李骞, 张峻. 基因多态性对肾移植患者他克莫司药代动力学影响的研究现状[J]. 中国临床药理学杂志, 2017, 33(23):2489-2492.
[12]	PRASAD N, JAISWAL A, BEHERA M R, et al. Melding pharmacogenomic effect of MDR1 and CYP3A5 gene polymorphism on tacrolimus dosing in renal transplant recipients in northern India[J]. Kidney Int Rep,2020,5(1):28-38.
[13]	FREDERICKS S, MORETON M, REBOUX S, et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements[J]. Transplantation,2006,82(5):705-708.
[14]	LOH P T, LOU H X, ZHAO Y, et al. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients[J]. Transplant Proc,2008,40(5):1690-1695.
[15]	GERVASINI G, GARCIA M, MACIAS R M, et al. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation[J]. Transpl Int,2012,25(4):471-480.

Name
E-mail
Phone
Title
Content
Verification Code

基因型	时间（周）	血药浓度（ng/ml）	给药剂量（m/mg）	浓度/剂量比（C/D）
CYP3A51/1 （AA）	1	13.3±6.0	4.4±2.1	3.6±3.0
	2	12.4±3.9	4.7±2.3	3.0±1.3
	3	12.6±4.7	4.5±2.0	3.0±0.9
	4	11.4±3.4	4.4±1.9	2.9±1.2
CYP3A51/3 （AG）	1	13.6±5.4	4.3±1.3	3.5±2
	2	14.7±5.4	4.1±1.4	4.0±2.0
	3	14.3±4.4	3.6±1.3	4.4±1.7
	4	12.0±3.3	3.1±1.3	4.3±1.6
CYP3A53/3 （GG）	1	14.9±6.6	3.1±1.2	5.6±3.7
	2	14.4±5.1	2.7±1.3	6.4±3.6
	3	13.7±4.4	2.4±1.2	7.1±4.7
	4	11.9±3.5	2.2±1.2	6.7±3.3

基因型	时间（周）	血药浓度（ng/ml）	给药剂量（m/mg）	浓度/剂量比（C/D）
MDR1（C1236T） CC	1	12.6±4.6	3.7±1.4	4.1±2.5
	2	15.4±5.3	3.4±1.7	5.2±1.9
	3	13.8±4.0	3.0±1.6	6.3±5.2
	4	12.0±2.6	2.8±1.7	5.7±3.4
MDR1（C1236T） CT	1	15.1±6.8	3.7±1.4	4.6±2.9
	2	13.6±4.9	3.5±1.6	5.0±3.5
	3	13.7±5.1	3.2±1.5	5.2±3.4
	4	11.8±3.4	2.9±1.4	5.1±2.8
MDR1（C1236T） TT	1	13.7±5.5	3.7±1.4	4.6±3.7
	2	15.0±5.4	3.4±1.6	5.3±3.1
	3	14.1±3.4	3.0±1.4	6.0±3.8
	4	12.0±3.7	2.6±1.3	5.8±3.0

基因型	时间（周）	血药浓度（ng/ml）	给药剂量（m/mg）	浓度/剂量比（C/D）
MDR1（G2677T/A） AA	1	12.5±0	3.9±0	3.2±0
	2	18.5±0	3.6±0	5.1±0
	3	9.9±0	3.4±0	2.9±0
	4	12.6±0	3.3±0	3.8±0
MDR1（G2677T/A） AT	1	15.8±6.2	3.8±1.5	5.0±3.7
	2	13.1±4.8	3.5±1.6	5.3±5.0
	3	12.6±4.1	3.4±1.6	4.3±1.9
	4	12.2±3.6	3.4±1.7	4.5±2.3
MDR1（G2677T/A） GA	1	13.5±6.6	3.4±1.2	4.5±2.8
	2	12.0±5.0	3.1±1.3	4.3±1.8
	3	13.2±4.6	2.9±1.3	5.4±2.8
	4	11.7±3.0	2.7±1.3	5.7±3.5
MDR1（G2677T/A） GG	1	14.1±6.0	3.9±1.6	4.1±2.2
	2	16.3±5.9	3.5±1.8	5.8±3.4
	3	15.9±5.0	3.0±1.8	7.6±6.1
	4	11.2±3.0	2.6±1.6	5.7±3.2
MDR1（G2677T/A） GT	1	14.7±6.6	3.7±1.5	4.8±3.5
	2	14.6±4.6	3.5±1.6	5.1±2.5
	3	13.6±4.3	3.0±1.4	5.5±2.9
	4	11.7±3.7	2.5±1.1	5.5±2.8
MDR1（G2677T/A） TT	1	12.8±4.0	3.5±1.1	4.4±3.4
	2	14.5±4.9	3.4±1.3	5.3±3.2
	3	13.7±2.3	3.1±1.2	5.2±2.5
	4	13.5±3.4	2.7±1.2	6.0±3.0

基因型	时间（周）	血药浓度（ng/ml）	给药剂量（m/mg）	浓度/剂量比（C/D）
MDR1（C3435T） CC	1	14.7±6.6	3.8±1.4	4.4±2.5
	2	14.8±5.5	3.4±1.6	5.3±3.0
	3	14.7±4.9	3.0±1.5	6.7±5.2
	4	11.8±3.0	2.6±1.4	5.8±3.4
MDR1（C3435T） CT	1	14.6±5.9	3.7±1.5	4.8±3.6
	2	14.1±4.8	3.5±1.6	5.1±3.3
	3	13.4±4.2	3.1±1.5	5.0±2.2
	4	11.7±3.7	2.8±1.4	5.0±2.4
MDR1（C3435T） TT	1	11.9±4.8	3.4±1.1	4.1±3.4
	2	14.4±5.5	3.3±1.3	5.2±3.2
	3	13.2±2.7	2.9±1.2	5.2±2.5
	4	13.0±3.6	2.6±1.2	5.9±2.9

Message Board

Effect of CYP3A5 and MDR1 gene polymorphism on blood concentration of tacrolimus and creatinine level in uremic patients during the early phase of kidney transplantation

doi: 10.12206/j.issn.1006-0111.202009087

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views